Hub : Traits :

Illnesses of father: Heart disease

67 significantly associated models · 20 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	109098737	110517617	3	1	4.1e-12	3.2e-12	1.0e+00	100	PSRC1
2	1	222096959	223537385	3	1	6.4e-09	5.5e-09	9.3e-02	92	AIDA
3	6	12020241	13990267	2	1	2.0e-10	1.1e-11	1.0e+00	100	RP1-257A7.5
4	6	160071844	161571560	2	2	7.4e-13	3.4e-14	1.1e-05	66	SLC22A1 SLC22A3
5	7	43719868	45228018	1	1	2.8e-08	1.7e-07	1.0e+00	100	NUDCD3
6	9	21303958	22819407	2	2	1.0e-20	3.3e-41	8.0e-21	52	CDKN2B CDKN2B-AS1
7	11	125979757	126556323	1	1	1.6e-08	1.0e-05	5.2e-03	60	ST3GAL4
8	15	78360691	79802863	2	2	6.7e-08	5.4e-07	1.9e-01	93	ADAMTS7 MORF4L1
9	15	90730363	92135418	1	1	8.5e-14	5.1e-11	9.7e-01	100	FES
10	16	81966047	84527021	1	1	2.8e-08	2.1e-08	1.6e-01	94	CDH13
11	17	1717695	2453908	1	1	1.7e-07	2.5e-08	1.0e-02	79	SMG6

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	41.14	3	2	4.4	0.00	1.0e+00	NUDCD3 PSRC1 ST3GAL4
Angina (self-reported)	25.66	9	9	20.0	0.99	5.1e-08	ADAMTS7 CDKN2B CDKN2B-AS1 FES MORF4L1 PSRC1 RP1-257A7.5 SLC22A1 SLC22A3
Coronary Artery Disease (CAD)	25.60	9	6	13.3	0.98	2.1e-06	ADAMTS7 CDKN2B CDKN2B-AS1 MORF4L1 PSRC1 RP1-257A7.5 SLC22A3 SMG6 ST3GAL4
Angina	24.74	9	9	20.0	0.99	8.5e-08	ADAMTS7 CDKN2B CDKN2B-AS1 FES MORF4L1 PSRC1 RP1-257A7.5 SLC22A1 SLC22A3
Heart attack/myocardial infarction (self-reported)	21.48	8	8	17.8	0.99	3.7e-06	AIDA CDKN2B CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A1 SLC22A3
High cholesterol (Self-reported)	21.46	6	4	8.9	0.86	2.9e-02	FES NUDCD3 PSRC1 SLC22A1 SLC22A3 ST3GAL4
Heart attack	21.39	8	8	17.8	0.99	2.5e-06	AIDA CDKN2B CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A1 SLC22A3
Medication: Cholesterol lowering	20.05	8	4	8.9	0.92	1.3e-03	AIDA CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3 ST3GAL4
Medication: Atorvastatin	14.26	5	3	6.7	0.97	6.1e-03	CDKN2B CDKN2B-AS1 PSRC1 SLC22A1 SLC22A3
Heart disease (mother)	13.98	9	3	6.7	0.97	1.4e-05	ADAMTS7 CDKN2B CDKN2B-AS1 FES MORF4L1 RP1-257A7.5 SLC22A1 SLC22A3 ST3GAL4
Medication: Simvastatin	13.46	7	2	4.4	0.91	4.4e-03	CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3 ST3GAL4
Medication: Aspirin	12.75	6	5	11.1	1.00	1.1e-05	CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3
Medication: Aspirin	12.49	6	5	11.1	1.00	1.9e-05	CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3
Heart disease (siblings)	11.45	8	1	2.2	0.98	1.3e-05	ADAMTS7 AIDA CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A1 SLC22A3
Cholesterol lowering medication	11.17	4	2	4.4	0.90	9.6e-02	CDKN2B PSRC1 SLC22A1 SLC22A3
Illnesses of father: None of the above (group 1)	10.51	5	2	4.4	-0.99	5.1e-04	CDKN2B CDKN2B-AS1 FES SLC22A3 ST3GAL4
Medication for cholesterol, blood pressure or diabetes	9.67	3	2	4.4	0.00	1.0e+00	FES PSRC1 SLC22A1
Cardiovascular Disease	7.34	5	3	6.7	0.98	4.6e-03	FES PSRC1 SLC22A1 SLC22A3 ST3GAL4
Vascular/heart problems diagnosed by doctor	7.11	4	1	2.2	-0.99	1.2e-02	FES SLC22A3 SMG6 ST3GAL4
Medication: Atenolol	7.10	2	1	2.2	0.00	1.0e+00	FES PSRC1
Diastolic blood pressure, automated reading	6.99	6	3	6.7	-0.07	9.0e-01	ADAMTS7 CDH13 CDKN2B CDKN2B-AS1 FES MORF4L1
Eye problems/disorders: Glaucoma	6.68	2	2	4.4	0.00	1.0e+00	CDKN2B CDKN2B-AS1
Father's age at death	6.60	4	1	2.2	-1.00	1.1e-03	CDKN2B CDKN2B-AS1 FES PSRC1
Systolic Blood Pressure	6.31	6	3	6.7	0.65	1.6e-01	CDH13 FES MORF4L1 RP1-257A7.5 SLC22A3 ST3GAL4
High blood pressure (mother)	6.23	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Medication for cholesterol	6.13	3	1	2.2	0.00	1.0e+00	FES PSRC1 SLC22A3
Hypertension (Self-reported)	5.96	2	1	2.2	0.00	1.0e+00	FES SMG6
High blood pressure	5.74	2	1	2.2	0.00	1.0e+00	FES SMG6
Glaucoma (self-reported)	5.60	2	1	2.2	0.00	1.0e+00	CDKN2B CDKN2B-AS1
Medication: Blood pressure	5.60	4	1	2.2	0.86	1.4e-01	ADAMTS7 FES SLC22A3 SMG6
Systolic blood pressure, automated reading	5.36	4	1	2.2	0.60	4.0e-01	CDH13 FES RP1-257A7.5 ST3GAL4
Medication: Blood pressure	5.33	2	1	2.2	0.00	1.0e+00	FES SLC22A1
Pack years adult smoking proportion	5.26	2	2	4.4	0.00	1.0e+00	ADAMTS7 MORF4L1
Pack years of smoking	4.86	2	2	4.4	0.00	1.0e+00	ADAMTS7 MORF4L1
Lung cancer (father)	4.84	3	0	0.0	0.00	1.0e+00	ADAMTS7 MORF4L1 NUDCD3
Illnesses of mother	4.40	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Headache pain in last month	4.28	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Illnesses of father: High blood pressure	4.27	1	1	2.2	0.00	1.0e+00	FES
Migraine (self-reported)	4.23	1	1	2.2	0.00	1.0e+00	RP1-257A7.5
Medication: Ramipril	4.07	1	0	0.0	0.00	1.0e+00	FES
Illnesses of siblings	4.03	2	1	2.2	0.00	1.0e+00	FES SMG6
Medication: Ibuprofen	3.93	2	1	2.2	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Medication: Ibuprofen (e.g. Nurofen)	3.85	2	1	2.2	0.00	1.0e+00	RP1-257A7.5 SLC22A3
High blood pressure (siblings)	3.77	2	1	2.2	0.00	1.0e+00	FES SMG6
Medication: Bendroflumethiazide	3.76	2	1	2.2	0.00	1.0e+00	ADAMTS7 FES
Heel T-Score	3.74	2	1	2.2	0.00	1.0e+00	PSRC1 SMG6
Pulse wave Arterial Stiffness index	3.63	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Pulse wave peak to peak time	3.57	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Schizophrenia (2014)	3.46	2	2	4.4	0.00	1.0e+00	FES SMG6
Number of treatments/medications taken	3.43	2	1	2.2	0.00	1.0e+00	FES PSRC1
Birth weight of first child	3.34	1	1	2.2	0.00	1.0e+00	FES
Chronic bronchitis/emphysema (father)	3.31	1	0	0.0	0.00	1.0e+00	ADAMTS7
Medication: Amlodipine	3.28	1	1	2.2	0.00	1.0e+00	FES
Schizophrenia (2018)	3.18	2	1	2.2	0.00	1.0e+00	FES SMG6
Bipolar Disorder or Schizophrenia	3.12	2	1	2.2	0.00	1.0e+00	FES SMG6
Number of self-reported non-cancer illnesses	3.11	1	0	0.0	0.00	1.0e+00	NUDCD3
Heel bone mineral density (BMD) T-score, automated (left)	2.95	1	1	2.2	0.00	1.0e+00	SMG6
Chest pain or discomfort	2.79	1	0	0.0	0.00	1.0e+00	CDKN2B
Blood Platelet Count	2.72	5	2	4.4	0.53	3.6e-01	ADAMTS7 CDKN2B NUDCD3 SLC22A3 SMG6
Basal cell carcinoma (self-reported)	2.69	1	0	0.0	0.00	1.0e+00	CDKN2B
Mineral and other dietary supplements	2.67	1	0	0.0	0.00	1.0e+00	FES
Multivitamins +/- minerals	2.60	1	0	0.0	0.00	1.0e+00	MORF4L1
Type 2 Diabetes (T2D) (2012)	2.59	1	0	0.0	0.00	1.0e+00	CDKN2B
Supplements: Fish oil (including cod liver oil)	2.59	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
Heel bone mineral density (BMD) T-score, automated (right)	2.53	1	1	2.2	0.00	1.0e+00	SMG6
Medication for pain relief, constipation, heartburn	2.53	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Breast cancer (self-reported)	2.49	1	0	0.0	0.00	1.0e+00	CDKN2B
Lung FEV1/FVC ratio	2.30	3	2	4.4	0.00	1.0e+00	AIDA PSRC1 SMG6
Breast Cancer	2.23	3	0	0.0	0.00	1.0e+00	CDKN2B CDKN2B-AS1 FES
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.22	3	0	0.0	0.00	1.0e+00	ADAMTS7 MORF4L1 NUDCD3
HDL Cholesterol	2.20	2	0	0.0	0.00	1.0e+00	PSRC1 ST3GAL4
Risk taking	2.17	1	0	0.0	0.00	1.0e+00	FES
Impedance of leg (right)	2.15	3	2	4.4	0.00	1.0e+00	AIDA FES SMG6
Impedance of leg (left)	2.10	3	2	4.4	0.00	1.0e+00	AIDA FES SMG6
Past tobacco smoking	2.07	1	0	0.0	0.00	1.0e+00	CDKN2B-AS1
Blood White Count	2.03	3	2	4.4	0.00	1.0e+00	CDKN2B FES SMG6
Medication: Paracetamol	2.03	1	1	2.2	0.00	1.0e+00	RP1-257A7.5
Mother's age at death	2.02	1	0	0.0	0.00	1.0e+00	SLC22A1
Number of operations (self-reported)	2.02	1	0	0.0	0.00	1.0e+00	NUDCD3
Waist Hip Ratio (WHR)	2.01	3	1	2.2	0.00	1.0e+00	ADAMTS7 SLC22A3 SMG6
Had other major operations	1.98	1	0	0.0	0.00	1.0e+00	NUDCD3
Smoking status: Previous	1.98	1	0	0.0	0.00	1.0e+00	CDKN2B-AS1
Alcohol usually taken with meals	1.95	1	0	0.0	0.00	1.0e+00	FES
Birth weight	1.92	1	1	2.2	0.00	1.0e+00	FES
Chronic bronchitis/emphysema (mother)	1.90	1	0	0.0	0.00	1.0e+00	MORF4L1
Smoking Status	1.89	1	0	0.0	0.00	1.0e+00	FES
Medication: Lisinopril	1.83	1	0	0.0	0.00	1.0e+00	FES
Alcohol intake frequency.	1.82	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Medication: Paracetamol	1.75	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Medication: Metformin	1.74	1	0	0.0	0.00	1.0e+00	CDKN2B
Neuroticism (Nagel 2018)	1.69	1	0	0.0	0.00	1.0e+00	SLC22A1
Respiratory disease	1.66	1	0	0.0	0.00	1.0e+00	FES
Ever smoked	1.64	1	0	0.0	0.00	1.0e+00	FES
Impedance of whole body	1.64	1	1	2.2	0.00	1.0e+00	SMG6
Hand grip strength (left)	1.62	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Handedness (chirality/laterality): Left-handed	1.60	1	0	0.0	0.00	1.0e+00	FES
Sensitivity / hurt feelings	1.59	1	1	2.2	0.00	1.0e+00	FES
Leg predicted mass (right)	1.57	5	1	2.2	-0.43	4.7e-01	FES NUDCD3 PSRC1 SLC22A3 SMG6
Allergy or Eczema	1.56	2	0	0.0	0.00	1.0e+00	FES SMG6
Neuroticism	1.56	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A1
Leg fat-free mass (right)	1.56	5	1	2.2	-0.43	4.7e-01	FES NUDCD3 PSRC1 SLC22A3 SMG6
Leg fat-free mass (left)	1.53	4	1	2.2	-0.40	6.0e-01	FES NUDCD3 SLC22A3 SMG6
Leg predicted mass (left)	1.53	5	1	2.2	-0.40	5.1e-01	FES NUDCD3 PSRC1 SLC22A3 SMG6
Hayfever, allergic rhinitis or eczema	1.50	1	0	0.0	0.00	1.0e+00	FES
Pulse rate, automated reading	1.49	2	0	0.0	0.00	1.0e+00	AIDA RP1-257A7.5
Pulse rate	1.48	1	0	0.0	0.00	1.0e+00	SLC22A1
Breastfed as a baby	1.48	1	0	0.0	0.00	1.0e+00	FES
Hip circumference	1.47	4	1	2.2	-0.62	3.8e-01	ADAMTS7 NUDCD3 SLC22A3 ST3GAL4
Whole body fat mass	1.46	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
Arm fat mass (left)	1.46	3	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3 SMG6
Arm fat mass (right)	1.44	3	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3 SMG6
Whole body fat-free mass	1.44	4	1	2.2	-0.49	5.1e-01	FES PSRC1 SLC22A3 SMG6
Arm fat percentage (right)	1.43	1	0	0.0	0.00	1.0e+00	NUDCD3
Long-standing illness, disability or infirmity	1.43	1	0	0.0	0.00	1.0e+00	CDKN2B
Weight	1.42	3	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3 SMG6
Trunk fat mass	1.41	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
Whole body water mass	1.41	4	1	2.2	-0.50	5.0e-01	FES PSRC1 SLC22A3 SMG6
Basal metabolic rate	1.40	3	1	2.2	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Hair/balding pattern: Pattern 2	1.39	1	0	0.0	0.00	1.0e+00	SMG6
Trunk fat-free mass	1.39	3	2	4.4	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Trunk predicted mass	1.37	3	2	4.4	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Pain experienced in last month	1.37	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Number of incorrect matches in round	1.36	1	0	0.0	0.00	1.0e+00	FES
Arm fat percentage (left)	1.36	1	0	0.0	0.00	1.0e+00	NUDCD3
Trunk fat percentage	1.31	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
Hair/balding pattern: Pattern 4	1.30	1	0	0.0	0.00	1.0e+00	FES
Body fat percentage	1.29	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
Allergy	1.28	1	0	0.0	0.00	1.0e+00	FES
Relative age of first facial hair	1.27	1	0	0.0	0.00	1.0e+00	SMG6
Arm predicted mass (left)	1.24	3	0	0.0	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Arm fat-free mass (right)	1.23	3	1	2.2	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Arm predicted mass (right)	1.22	3	0	0.0	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Arm fat-free mass (left)	1.21	3	1	2.2	0.00	1.0e+00	PSRC1 SLC22A3 SMG6
Impedance of arm (right)	1.19	1	1	2.2	0.00	1.0e+00	SMG6
Mean time to correctly identify matches	1.19	1	0	0.0	0.00	1.0e+00	FES
Leg fat mass (right)	1.18	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
Hand grip strength (right)	1.16	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Impedance of arm (left)	1.16	1	1	2.2	0.00	1.0e+00	SMG6
Waist circumference	1.15	1	0	0.0	0.00	1.0e+00	SMG6
Worry (Nagel 2018)	1.14	1	0	0.0	0.00	1.0e+00	SLC22A1
Leg fat mass (left)	1.13	2	0	0.0	0.00	1.0e+00	NUDCD3 SLC22A3
BMI	1.12	2	0	0.0	0.00	1.0e+00	SLC22A3 SMG6
Body mass index (BMI)	1.03	1	0	0.0	0.00	1.0e+00	SMG6
Comparative body size at age 10	0.92	1	0	0.0	0.00	1.0e+00	SMG6
Comparative height size at age 10	0.88	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Intelligence (Savage-Jansen 2018)	0.76	1	0	0.0	0.00	1.0e+00	NUDCD3
Lung FVC	0.70	2	0	0.0	0.00	1.0e+00	AIDA NUDCD3
Sitting height	0.68	3	0	0.0	0.00	1.0e+00	FES MORF4L1 SLC22A3
Height	0.63	4	3	6.7	-0.75	2.5e-01	FES NUDCD3 PSRC1 SLC22A3
Blood Red Count	0.61	3	0	0.0	0.00	1.0e+00	FES RP1-257A7.5 SMG6
Standing height	0.61	3	1	2.2	0.00	1.0e+00	NUDCD3 PSRC1 SLC22A3
Blood Eosinophil Count	0.48	1	0	0.0	0.00	1.0e+00	ST3GAL4
Hair Pigment	0.44	4	3	6.7	-0.83	1.7e-01	ADAMTS7 CDKN2B CDKN2B-AS1 FES

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Artery Aorta	3	0.101	1.5
GTEx	Artery Coronary	1	0.085	1.5
GTEx	Artery Tibial	2	0.053	1.5
GTEx	Brain Frontal Cortex BA9	1	0.108	1.5
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.5
GTEx	Liver	1	0.139	1.5
GTEx	Ovary	0	0.000	1.5
GTEx	Uterus	0	0.000	1.5
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.194	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.5
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.5
GTEx	Adipose Subcutaneous	0	0.000	1.4
GTEx	Adipose Visceral Omentum	1	0.049	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.4
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.4
GTEx	Brain Cerebellum	0	0.000	1.4
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Hippocampus	0	0.000	1.4
GTEx	Brain Hypothalamus	1	0.169	1.4
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.4
GTEx	Breast Mammary Tissue	0	0.000	1.4
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.4
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.4
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.4
GTEx	Cells Transformed fibroblasts	2	0.048	1.4
GTEx	Colon Sigmoid	1	0.068	1.4
GTEx	Esophagus Mucosa	1	0.030	1.4
GTEx	Esophagus Muscularis	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Lung	1	0.035	1.4
GTEx	Muscle Skeletal	2	0.069	1.4
GTEx	Nerve Tibial	1	0.023	1.4
GTEx	Pancreas	0	0.000	1.4
GTEx	Pituitary	0	0.000	1.4
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	1.4
GTEx	Skin Sun Exposed Lower leg	3	0.082	1.4
GTEx	Thyroid	1	0.025	1.4
GTEx	Whole Blood	3	0.151	1.4
METSIM	Adipose	2	0.043	1.4
NTR	Blood	0	0.000	1.4
ROSMAP	Brain Pre-frontal Cortex	3	0.068	1.4
YFS	Blood	2	0.043	1.4
CommonMind	Brain Pre-frontal Cortex	4	0.074	1.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	3	0.068	1.4
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.4
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	1	0.037	1.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	1	0.023	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	1	0.034	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	1	0.040	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	2	0.126	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	3	0.065	1.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.4
The Cancer Genome Atlas	Thyroid Carcinoma	1	0.019	1.4
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.4
GTEx	Adrenal Gland	0	0.000	1.3
GTEx	Colon Transverse	0	0.000	1.3
GTEx	Heart Atrial Appendage	0	0.000	1.3
GTEx	Prostate	0	0.000	1.3
GTEx	Small Intestine Terminal Ileum	0	0.000	1.3
GTEx	Spleen	0	0.000	1.3
GTEx	Stomach	0	0.000	1.3
GTEx	Testis	0	0.000	1.3
GTEx	Vagina	0	0.000	1.3
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.3